Bookmarks
TNT: Triple Negative breast cancer Trial
Population Size
Not reported
Years
2007
Associated BioSamples
Availability to be confirmed
Geographic coverage
United Kingdom
England
Lead time
Other
Summary
Collection of samples and data across the following diseases: Malignant tumour of breast
Documentation
TNT is a phase III, multi centre, randomised trial of carboplatin versus docetaxel in women with ER-, PgR- and HER2- metastatic or recurrent locally advanced breast cancer. Patients will be randomised (1:1) to carboplatin or docetaxel and will cross over to the alternative treatment (docetaxel (if randomised to carboplatin) or carboplatin (if randomised to docetaxel)) on progression. Trial Treatment: Group A: Carboplatin AUC 6, q 3 weeks for 6 cycles (18 weeks) Group B: Docetaxel 100mg/m2, q 3 weeks for 6 cycles (18 weeks) On evidence of disease progression, patients will cross over to the alternative treatment.
Dataset type
Health and disease
Dataset sub-type
Not applicable
Keywords
Breast Cancer, Trial, UKCRC Tissue Directory, Malignant tumour of breast, Triple Negative, TNT
Provenance
Image contrast
Not stated
Biological sample availability
Availability to be confirmed
Details
Publishing frequency
Other
Version
1.0.0
Modified
08/10/2024
Citation Requirements
In Progress
Coverage
Start date
01/01/2007
Time lag
Variable
Geographic coverage
United Kingdom, England
Accessibility
Language
en
Controlled vocabulary
LOCAL
Format
In Progress
Data Access Request
Dataset pipeline status
Not available
Access rights
Please contact the publisher using Contact Point details provided
Time to dataset access
Other
Access request cost
Not specified
Access method category
Varies based on project
Data Controller
The Institute of Cancer Research